HUMA Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
Humacyte Inc (HUMA) is not a strong buy for a beginner, long-term investor at this time. While the technical indicators show some positive momentum, the company's financial performance is weak, with significant declines in net income and EPS. Additionally, there are no recent positive news catalysts or significant insider/hedge fund activity to support a strong buy recommendation. The options data indicates low put-call ratios, suggesting bullish sentiment, but this alone does not outweigh the other negative factors. Given the investor's scenario, holding off on this stock for now is the most prudent action.
The MACD is positive and expanding (0.0214), indicating bullish momentum. RSI is at 70.947, in the neutral zone, and moving averages are converging. The stock is trading near its resistance level (R1: 1.226), with a slight pre-market increase of 3.45%. However, the stock's historical trend suggests a potential decline in the next month (-15.11%).
Bullish options sentiment with low put-call ratios. MACD indicates positive momentum. Gross margin remains stable at 65.47%.
Stock trend analysis predicts a potential decline of -15.11% in the next month.
In Q3 2025, revenue remained flat at $753,000 (0% YoY growth). Net income dropped significantly to -$17.51M (-55.33% YoY), and EPS fell to -0.11 (-66.67% YoY). Gross margin remained stable at 65.47%. Overall, the financials indicate poor performance with no growth.
Benchmark maintains a Buy rating but has lowered the price target from $11 to $10, citing recent financing activity. This indicates reduced confidence in the stock's near-term potential.
